Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 610-613

  Goldner, Thomas ^a   Hempel, Christine ^a   Ruebsamen Schaeff, Helga ^a   Zimmermann, Holger ^a   Lischka, Peter ^a  

^a AiCuris GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; ENHANCED GREEN FLUORESCENT PROTEIN; FOSCARNET; GANCICLOVIR; LETERMOVIR; TOMEGLOVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; DRUG EXPOSURE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; MUTANT; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CHARACTERIZATION;

ACETATES; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; HUMANS; QUINAZOLINES;

EID: 84891504725     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01794-13     Document Type: Article

References (19)

1. Harter G, Michel D. 2012. Antiviral treatment of cytomegalovirus infection: an update. Expert Opin. Pharmacother. 13:623-627. http://dx.doi.org/10.1517/14656566.2012.658775.
2. Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T, Michel D. 2009. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin. Pharmacother. 10:191-209. http://dx.doi.org/10.1517/14656560802678138.
3. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712. http://dx.doi.org/10.1128/ CMR.00009-10.
4. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. 2011. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J. Virol. 85:10884-10893. http://dx.doi.org/10.1128/JVI.05265-11.
5. Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, Ruebsamen-Schaeff H, Zimmermann H. 2010. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Anti- microb. Agents Chemother. 54:1290 -1297. http://dx.doi.org/10.1128/AAC.01596-09.
6. Chemaly RF, Ehninger G, Champlin R, Richard MP, Zimmermann H, Lischka P, Stoelben S, McCormick D, Ruebsamen-Schaeff H. 2012. Letermovir (AIC246) for the prevention ofCMVinfections meets primary endpoint in phase 2b trial in human blood precursor cell transplant (HBPCT) recipients, abstr. T-356. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother.
7. Marschall M, Stamminger T, Urban A, Wildum S, Ruebsamen- Schaeff H, Zimmermann H, Lischka P. 2012. In vitro evaluation of the activities of the novel anti-cytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob. Agents Chemother. 56:1135-1137. http://dx.doi.org/10.1128/AAC.05908-11.
8. Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P, Zimmermann H, Rubsamen-Schaeff H. 2011. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am. J. Transplant. 11:1079-1084. http://dx.doi.org/10.1111/j.1600-6143. 2011.03530.x.
9. Boeckh M, Boivin G. 1998. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin. Microbiol. Rev. 11:533-554.
10. Chevillotte M, von EJ, Meier BM, Lin FM, Kestler HA, Mertens T. 2010. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res. 85:318-327. http://dx.doi.org/10.1016/j.antiviral. 2009.10.004.
11. Borst EM, Kleine-Albers J, Gabaev I, Babic M, Wagner K, Binz A, Degenhardt I, Kalesse M, Jonjic S, Bauerfeind R, Messerle M. 2013. The human cytomegalovirus UL51 protein is essential for viral genome cleavage- packaging and interacts with the terminase subunits pUL56 and pUL89. J. Virol. 87:1720-1732. http://dx.doi.org/10.1128/JVI.01955-12.
12. Bradley AJ, Lurain NS, Ghazal P, Trivedi U, Cunningham C, Baluchova K, Gatherer D, Wilkinson GW, Dargan DJ, Davison AJ. 2009. Highthroughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. J. Gen. Virol. 90:2375-2380. http://dx.doi.org/10.1099/vir.0.013250-0.
13. Champier G, Hantz S, Couvreux A, Stuppfler S, Mazeron MC, Bouaziz S, Denis F, Alain S. 2007. New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. Antivir. Ther. 12:217-232.
14. Tischer BK, von EJ, Kaufer B, Osterrieder N. 2006. Two-step redmediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40:191-197. http://dx.doi.org/10.2144/000112096.
15. Tavalai N, Kraiger M, Kaiser N, Stamminger T. 2008. Insertion of an EYFP-pp71 (UL82) coding sequence into the human cytomegalovirus genome results in a recombinant virus with enhanced viral growth. J. Virol. 82:10543-10555. http://dx.doi.org/10.1128/JVI.01006-08.
16. Reefschlaeger J, Bender W, Hallenberger S, Weber O, Eckenberg P, Goldmann S, Haerter M, Buerger I, Trappe J, Herrington JA, Haebich D, Ruebsamen-Waigmann H. 2001. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 48:757-767. http://dx.doi.org/10.1093/jac/48.6.757.
17. Underwood MR, Harvey RJ, Stanat SC, Hemphill ML, Miller T, Drach JC, Townsend LB, Biron KK. 1998. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72:717-725.
18. Buerger I, Reefschlaeger J, Bender W, Eckenberg P, Popp A, Weber O, Graeper S, Klenk HD, Ruebsamen-Waigmann H, Hallenberger S. 2001. Anovel nonnucleoside inhibitor specifically targets cytomegalovirusDNA maturation via the UL89 and UL56 gene products. J. Virol. 75:9077-9086. http://dx.doi.org/10. 1128/JVI.75.19.9077-9086.2001.
19. Champier G, Couvreux A, Hantz S, Rametti A, Mazeron MC, Bouaziz S, Denis F, Alain S. 2008. Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. Antivir. Ther. 13:643-654.